Probi AB (publ) (PROB.ST)
SEK 347.0
(-0.29%)
SEK 347.0
(-0.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 16.81 Million SEK | -58.6% |
| 2022 | 40.62 Million SEK | -51.14% |
| 2021 | 83.14 Million SEK | -10.3% |
| 2020 | 92.69 Million SEK | 7.92% |
| 2019 | 85.88 Million SEK | 12.64% |
| 2018 | 76.25 Million SEK | 10.36% |
| 2017 | 69.09 Million SEK | -36.36% |
| 2016 | 108.56 Million SEK | 121.39% |
| 2015 | 49.03 Million SEK | 125.31% |
| 2014 | 21.76 Million SEK | 44.67% |
| 2013 | 15.04 Million SEK | 11.4% |
| 2012 | 13.5 Million SEK | -4.85% |
| 2011 | 14.19 Million SEK | 3.89% |
| 2010 | 13.66 Million SEK | 27.07% |
| 2009 | 10.75 Million SEK | 34.47% |
| 2008 | 7.99 Million SEK | -67.4% |
| 2007 | 24.52 Million SEK | 607.41% |
| 2006 | -4.83 Million SEK | -154.73% |
| 2005 | 8.83 Million SEK | 19.92% |
| 2004 | 7.36 Million SEK | -9.95% |
| 2003 | 8.18 Million SEK | -42.1% |
| 2002 | 14.12 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 3.57 Million SEK | -55.53% |
| 2024 Q1 | 1.85 Million SEK | 171.54% |
| 2024 Q2 | 8.04 Million SEK | 334.11% |
| 2023 Q3 | 6.39 Million SEK | 202.16% |
| 2023 Q2 | -6.26 Million SEK | -132.48% |
| 2023 Q4 | -2.59 Million SEK | -140.5% |
| 2023 Q1 | 19.27 Million SEK | 436.19% |
| 2023 FY | 16.81 Million SEK | -58.6% |
| 2022 Q3 | 12.36 Million SEK | -38.09% |
| 2022 Q2 | 19.97 Million SEK | 42.46% |
| 2022 FY | 40.62 Million SEK | -51.14% |
| 2022 Q4 | -5.73 Million SEK | -146.36% |
| 2022 Q1 | 14.01 Million SEK | -46.63% |
| 2021 Q4 | 26.26 Million SEK | 42.34% |
| 2021 Q1 | 22.63 Million SEK | 3.68% |
| 2021 Q2 | 15.79 Million SEK | -30.24% |
| 2021 Q3 | 18.45 Million SEK | 16.87% |
| 2021 FY | 83.14 Million SEK | -10.3% |
| 2020 Q3 | 33.17 Million SEK | 22.78% |
| 2020 Q2 | 27.02 Million SEK | 153.28% |
| 2020 FY | 92.69 Million SEK | 7.92% |
| 2020 Q1 | 10.66 Million SEK | -58.72% |
| 2020 Q4 | 21.83 Million SEK | -34.19% |
| 2019 Q2 | 29.83 Million SEK | 249.65% |
| 2019 Q1 | 8.53 Million SEK | -64.27% |
| 2019 Q3 | 21.67 Million SEK | -27.35% |
| 2019 Q4 | 25.84 Million SEK | 19.21% |
| 2019 FY | 85.88 Million SEK | 12.64% |
| 2018 Q3 | 28.1 Million SEK | 34.08% |
| 2018 Q1 | 3.3 Million SEK | 243.6% |
| 2018 FY | 76.25 Million SEK | 10.36% |
| 2018 Q4 | 23.88 Million SEK | -15.01% |
| 2018 Q2 | 20.96 Million SEK | 534.77% |
| 2017 Q3 | 8.81 Million SEK | -45.54% |
| 2017 Q2 | 16.17 Million SEK | -62.5% |
| 2017 Q1 | 43.14 Million SEK | 17.11% |
| 2017 Q4 | 961 Thousand SEK | -89.09% |
| 2017 FY | 69.09 Million SEK | -36.36% |
| 2016 Q3 | 27.71 Million SEK | 62.21% |
| 2016 Q1 | 26.93 Million SEK | 887.53% |
| 2016 FY | 108.56 Million SEK | 121.39% |
| 2016 Q4 | 36.84 Million SEK | 32.94% |
| 2016 Q2 | 17.08 Million SEK | -36.56% |
| 2015 Q3 | 13.13 Million SEK | 21.57% |
| 2015 Q2 | 10.8 Million SEK | -51.68% |
| 2015 Q4 | 2.72 Million SEK | -79.24% |
| 2015 FY | 49.03 Million SEK | 125.31% |
| 2015 Q1 | 22.36 Million SEK | 316.83% |
| 2014 Q4 | 5.36 Million SEK | -23.91% |
| 2014 FY | 21.76 Million SEK | 44.67% |
| 2014 Q3 | 7.05 Million SEK | 63.51% |
| 2014 Q2 | 4.31 Million SEK | -14.32% |
| 2014 Q1 | 5.03 Million SEK | 92.5% |
| 2013 Q2 | 3.82 Million SEK | -21.94% |
| 2013 Q1 | 4.9 Million SEK | 128.46% |
| 2013 FY | 15.04 Million SEK | 11.4% |
| 2013 Q4 | 2.61 Million SEK | -29.25% |
| 2013 Q3 | 3.69 Million SEK | -3.47% |
| 2012 Q3 | 2.94 Million SEK | 49.39% |
| 2012 FY | 13.5 Million SEK | -4.85% |
| 2012 Q1 | 6.43 Million SEK | 2209.84% |
| 2012 Q2 | 1.97 Million SEK | -69.32% |
| 2012 Q4 | 2.14 Million SEK | -27.2% |
| 2011 Q2 | 4.91 Million SEK | -3.61% |
| 2011 Q3 | 4.48 Million SEK | -8.77% |
| 2011 Q4 | -305 Thousand SEK | -106.8% |
| 2011 FY | 14.19 Million SEK | 3.89% |
| 2011 Q1 | 5.09 Million SEK | 112.9% |
| 2010 Q1 | 2.41 Million SEK | 0.0% |
| 2010 FY | 13.66 Million SEK | 27.07% |
| 2010 Q3 | 6.72 Million SEK | 215.58% |
| 2010 Q4 | 2.39 Million SEK | -64.39% |
| 2010 Q2 | 2.13 Million SEK | -11.58% |
| 2009 FY | 10.75 Million SEK | 34.47% |
| 2008 FY | 7.99 Million SEK | -67.4% |
| 2007 FY | 24.52 Million SEK | 607.41% |
| 2006 FY | -4.83 Million SEK | -154.73% |
| 2005 FY | 8.83 Million SEK | 19.92% |
| 2004 FY | 7.36 Million SEK | -9.95% |
| 2003 FY | 8.18 Million SEK | -42.1% |
| 2002 FY | 14.12 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 222.847% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 145.253% |
| BioGaia AB (publ) | 365.35 Million SEK | 95.396% |
| Enzymatica AB (publ) | -49.72 Million SEK | 133.822% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 137.7% |
| Gabather AB (publ) | -9.43 Million SEK | 278.224% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 147.001% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | 179.737% |
| Nanexa AB (publ) | -76.39 Million SEK | 122.015% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | 209.179% |
| ODI Pharma AB | 355.97 Thousand SEK | -4624.823% |
| Orexo AB (publ) | -128.3 Million SEK | 113.109% |
| Swedencare AB (publ) | 58.6 Million SEK | 71.299% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 99.302% |
| Toleranzia AB | -7.45 Million SEK | 325.486% |
| Vivesto AB | -367.03 Million SEK | 104.582% |